Core Viewpoint - CVS Health is a significant player in the healthcare sector, with a diverse range of services and is set to release its quarterly earnings on February 10, 2026, with estimated EPS of $0.99 and revenue of approximately $103.57 billion [1][6] Financial Performance - CVS has consistently exceeded earnings estimates over the past four quarters, indicating strong financial performance [2] - For Q4 2025, analysts expect non-GAAP earnings of $0.99 per share, a decline from $1.19 per share in Q4 2024, potentially influenced by Medicare news [3] Market Valuation - CVS's P/E ratio of 212 suggests that investors are willing to pay a high price for its earnings, reflecting high expectations [3] - The price-to-sales ratio of 0.25 indicates that the market values CVS at 25 cents for every dollar of sales, while the enterprise value to sales ratio of 0.44 reflects its valuation in relation to sales [4] - The enterprise value to operating cash flow ratio of 18.89 highlights how the market values CVS's cash-generating ability [4] Capital Structure - CVS's debt-to-equity ratio of 1.12 shows a moderate use of debt in its capital structure [5] - The current ratio of 0.83 suggests potential liquidity concerns, as CVS has less than one dollar in current assets for every dollar of current liabilities [5] - The earnings yield of 0.47% provides a comprehensive view of CVS's financial health and market valuation [5]

Group 1 - The Federal Reserve's dual mandate will be addressed this week with the release of the January jobs report and the consumer price index [1] - Earnings reports from Cisco Systems, Applied Materials, and Arista are anticipated, which may provide insights into their financial performance and market conditions [1]

Core Viewpoint - The State Street SPDR Portfolio Long Term Corporate Bond ETF (SPLB) and Schwab Long-Term U.S. Treasury ETF (SCHQ) differ significantly in yield, sector exposure, and risk, with SPLB focusing on corporate bonds for higher income potential while SCHQ offers a Treasury focus at a slightly lower cost [1][2]. Cost and Size Comparison - SPLB has an expense ratio of 0.04% while SCHQ is slightly lower at 0.03% - The one-year return for SPLB is 6.47% compared to SCHQ's 4.17% - SPLB offers a higher dividend yield of 5.2% versus SCHQ's 4.6% - SPLB has a total assets under management (AUM) of $1.2 billion, while SCHQ has $902.5 million [3]. Performance and Risk Comparison - Over the past five years, SPLB experienced a maximum drawdown of 34.40%, while SCHQ faced a larger drawdown of 46.13% - An investment of $1,000 would have grown to $706 in SPLB and $599 in SCHQ over the same period [4]. Fund Composition - SCHQ primarily tracks the long-term U.S. Treasury bond market, holding 98 positions with 91% in government securities, indicating low exposure to corporate credit risk [5]. - SPLB invests in nearly 3,000 long-term, investment-grade U.S. corporate bonds, providing broad issuer diversification and higher credit risk, with top holdings including Anheuser Busch InBev, Meta Platforms, and CVS Health [7]. Investment Implications - Investing in SCHQ offers high credit quality and serves as a hedge against equity market volatility, making it suitable for safety and capital preservation [9][10]. - SPLB, while riskier due to its corporate bond holdings, provides higher income potential, making it attractive for those seeking diversity and income generation [11][12].

Core Insights - CVS Health announced that its approximately 9,000 community pharmacies are now accepting TrumpRx discount cards, which provide savings on certain medications for eligible individuals as determined by drug manufacturers [1] Company Summary - CVS Health is expanding its services by integrating TrumpRx discount cards into its community pharmacies, enhancing access to medication savings for eligible patients [1]

Aetna, a CVS Health business, serves an estimated 37 million people with information and resources to help them make better informed decisions about their health care. Aetna offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, and medical management capabilities, Medicaid health care management services, workers' compensation administrative services and health information technolo ...

Core Viewpoint - CVS Health is set to report its fourth-quarter 2025 results on February 10, with expectations of continued revenue growth despite a projected decline in earnings per share [1][2]. Group 1: Earnings and Revenue Estimates - The Zacks Consensus Estimate for CVS's fourth-quarter revenues is $103.1 billion, indicating a 5.5% growth from the previous year [2]. - The earnings estimate for the fourth quarter is 99 cents per share, reflecting a 16.8% decrease compared to the same period last year [2]. - Earnings estimates have increased by 3.1% over the past 60 days, indicating positive sentiment leading up to the earnings announcement [3]. Group 2: Factors Influencing Performance - The Health Care Benefits segment is expected to face challenges due to elevated medical costs and pressures from the Medicaid business, which may impact revenue [4]. - Positive contributions to revenue may come from the government business, particularly due to the Inflation Reduction Act's effects on the Medicare Part D program [5]. - Aetna's integration of pharmacy prescriptions and medical procedures is anticipated to enhance operational efficiency and revenue in the Health Care Benefits segment [6]. Group 3: Segment Performance Insights - The Pharmacy & Consumer Wellness segment is likely to have driven revenue growth, supported by the Rite Aid acquisition and increased prescription volume [9]. - The Health Services segment is projected to see a 7.2% year-over-year revenue increase, despite some short-term headwinds affecting client contracts [12]. - The Pharmacy & Consumer Wellness segment is expected to grow by 9.8% in the fourth quarter, benefiting from a favorable pharmacy drug mix and higher prescription volumes [15]. Group 4: Strategic Developments - CVS has completed a review of its Oak Street clinic operations, leading to the closure of underperforming locations, which is expected to improve revenue [11]. - The company is also planning to reduce the number of new Oak Street clinics to focus on sustainable margins [11]. - CVS is actively offering updated COVID-19 vaccines across its locations, which is expected to positively impact revenues in the fourth quarter [14].

I aim to invest in companies with perfect qualitative attributes, buy them at an attractive price based on fundamentals, and hold them forever. I hope to publish articles covering such companies approximately 3 times per week, with extensive quarterly follow-ups and constant updates.I manage a concentrated portfolio targeted at avoiding losers and maximizing exposure to big winners. This means that often I'll rate great companies at a 'Hold' because their growth opportunity is below my threshold, or their d ...

I aim to invest in companies with perfect qualitative attributes, buy them at an attractive price based on fundamentals, and hold them forever. I hope to publish articles covering such companies approximately 3 times per week, with extensive quarterly follow-ups and constant updates.I manage a concentrated portfolio targeted at avoiding losers and maximizing exposure to big winners. This means that often I'll rate great companies at a 'Hold' because their growth opportunity is below my threshold, or their d ...

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for CVS Health despite higher revenues, with a focus on how actual results will compare to estimates [1] Earnings Expectations - CVS Health is expected to report quarterly earnings of $0.99 per share, reflecting a year-over-year decrease of 16.8% [3] - Revenue projections stand at $103.13 billion, indicating a 5.5% increase from the previous year [3] Estimate Revisions - The consensus EPS estimate has been revised down by 0.1% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for CVS Health is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.38% [12] Earnings Surprise Prediction - A positive Earnings ESP is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10] - CVS Health currently holds a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [12] Historical Performance - CVS Health has consistently beaten consensus EPS estimates, achieving this in the last four quarters [14] - In the last reported quarter, CVS Health exceeded expectations by delivering earnings of $1.60 per share against an expected $1.36, resulting in a surprise of +17.65% [13] Market Reaction - The stock price may increase if earnings exceed expectations, while a miss could lead to a decline [2] - Other factors beyond earnings results may also influence stock movement, highlighting the complexity of market reactions [15]

CVS Health Corporation (NYSE:CVS) is flat on Wednesday. The shares dropped by almost 15% yesterday after it was reported that Medicare was proposing rates that are well below expectations. • What’s driving CVS shares today?If the shares continue to trend lower, they may find support around $70. They may even rally off this level. This is why CVS is the Stock of the Day.Successful traders understand which price levels in a market are important. These are called support and resistance levels.If a stock is tre ...